Loss of Claudin-3 Impairs Hepatic Metabolism, Biliary Barrier Function, and Cell Proliferation in the Murine Liver

Felix Alexander Baier,¹ Daniel Sánchez-Taltavull,¹ Tural Yarahmadov,¹ Cristina Gómez Castellà,² Fadi Jebbawi,² Adrian Keogh,¹ Riccardo Tombolini,¹ Adolfo Odriozola,³ Mariana Castro Dias,¹ Urban Deutsch,⁴ Mikio Furuse,⁵ Britta Engelhardt,⁴ Benoît Zuber,³ Alex Odermatt,² Daniel Candinas,¹ and Deborah Stroka¹

¹Visceral Surgery and Medicine, Inselspital, Bern University Hospital, Department for BioMedical Research, ²Institute of Anatomy, ³Theodor Kocher Institute, University of Bern, Bern, Switzerland; ⁴Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; ⁵Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Japan

SUMMARY
Delineating the cell type–specific expression of hepatic tight junction genes showed that claudin-3 is the predominant tight junction protein on hepatocytes and cholangiocytes. In vivo study of claudin-3 knockout mice showed that claudin-3 is necessary to maintain lipid metabolism, biliary-barrier function, and optimal liver regeneration.

BACKGROUND & AIMS: Tight junctions in the liver are essential to maintain the blood-biliary barrier, however, the functional contribution of individual tight junction proteins to barrier and metabolic homeostasis remains largely unexplored. Here, we describe the cell type–specific expression of tight junction genes in the murine liver, and explore the regulation and functional importance of the transmembrane protein claudin-3 in liver metabolism, barrier function, and cell proliferation.

METHODS: The cell type–specific expression of hepatic tight junction genes is described using our mouse liver single-cell sequencing data set. Differential gene expression in Cldn3−/− and Cldn3+/+ livers was assessed in young and aged mice by RNA sequencing (RNA-seq), and hepatic tissue was analyzed for lipid content and bile acid composition. A surgical model of partial hepatectomy was used to induce liver cell proliferation.

RESULTS: Claudin-3 is a highly expressed tight junction protein found in the liver and is expressed predominantly in hepatocytes and cholangiocytes. The histology of Cldn3−/− livers showed no overt phenotype, and the canalicular tight junctions appeared intact. Nevertheless, by RNA-seq we detected a down-regulation of metabolic pathways in the livers of Cldn3−/− young and aged mice, as well as a decrease in lipid content and a weakened biliary barrier for primary bile acids, such as taurocholic acid, taurochenodeoxycholic acid, and taurine-conjugated muricholic acid. Coinciding with defects in the biliary barrier and lower lipid metabolism, there was a diminished hepatocyte proliferative response in Cldn3−/− mice after partial hepatectomy.

CONCLUSIONS: Our data show that, in the liver, claudin-3 is necessary to maintain metabolic homeostasis, retention of bile acids, and optimal hepatocyte proliferation during liver regeneration. The RNA-seq data set can be accessed at: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159914. (Cell Mol Gastroenterol Hepatol 2021;12:745–767; https://doi.org/10.1016/j.jcmgh.2021.04.003)

Keywords: Tight Junction; Bile Acid; Liver Regeneration; Claudin; Single-Cell RNA Sequencing.
tight junction (TJ) proteins can be found in almost every organ of the body, where their primary function is to create a semipermeable paracellular barrier that restricts passage of ions and solutes. TJ protein expression is highly organ-specific. In the liver, TJs act as a separator of bile and blood circulation in hepatocytes and cholangiocytes. The molecular components of hepatic TJs comprise a number of different transmembrane and cytoplasmic proteins that have varying expression intensity and localization within the tissue. Thus far, the cell type–specific expression of hepatic TJ proteins has remained largely unexplored.

The protein family that best defines the barrier and sealing properties of a TJ are the claudins. Claudins are transmembrane proteins that have 27 known family members in human beings. Structurally, claudins consist of 4 transmembrane segments, 2 extracellular loops, and 1 intracellular loop, with the N-terminus and C-terminus facing the cytosol. The C-terminal end also harbors the Post synaptic density95 loop, with the N-terminus and C-terminus facing the cytosol. Previous reports have shown that claudins of both sealing and pore-forming types can be found in liver tissue. Mutations and/or abnormal expression of claudin proteins is associated with multiple hepatic morbidities such as hepatomegaly, jaundice, portal hypertension, restricted bile flow, or cirrhosis. For example, absence of sealing claudin-1 may cause the rare genetic disease neonatal ichthyosis and sclerosing cholangitis, in which patients present with cholestasis and increased serum levels of γ-glutamyltransferase, transaminase activity, and bilirubin. Knockout of pore-forming claudin-2 on the other hand reduces bile flow and concentrates lipids and acids within the hepatic bile of mice. Claudin-3 is another sealing-type claudin that controls the barrier for calcium phosphate ions. Intestinal studies have shown that claudin-3 expression changes in high-fat or inflammatory environments, suggesting a role for metabolic regulation. Until now, it was not known if claudin-3 contributed to liver lipid metabolism or regenerative recovery after tissue loss.

Using data from single-cell RNA sequencing, we delineate the cell type–specific TJ gene expression of a mouse liver. We identified Cldn3 as one of the most abundant transmembrane TJ genes in the liver with expression in hepatocytes and cholangiocytes. Using Cldn3−/− mice, we found that claudin-3 is essential for the liver’s metabolic homeostasis and that loss of claudin-3 impairs hepatocyte proliferation after partial hepatectomy (PHx).

Results

Expression Profile of TJ Genes in Hepatic Cells

To describe the hepatic expression of TJ genes, we used our recently published single-cell RNA sequencing (scRNA-seq) data set of parenchymal and nonparenchymal cells from a C57BL/6 liver. Unsupervised clustering identified 14 unique cell clusters (Figure 1A). A defined set of marker genes and clustering for cell classification identified the populations of hepatocytes, cholangiocytes, endothelial cells, immune cells, and stellate cells (Figure 1B). Expression of TJ genes within these 5 populations is shown in the heatmap, with hepatocytes expressing Cldn3, Cldh5, Cldh12, Jam-a, and Pard3. Cholangiocytes expressed high levels of Cldh3, Cldh6, Cldh7, and Jam-a. Endothelial and stellate cells expressed mostly Cldh5, but also Jam-a, Jam-b, and others. TJ messenger RNA (mRNA) also could be detected in immune cells, including Cldn5, Jam-a, Sympk, and Ybx3 (Figure 1C). Some TJ genes, such as Jam-a and Ybx3, were expressed over several cell populations. We observed that Cldn3 is the TJ gene with the highest mRNA expression in hepatocytes and cholangiocytes (Figure 1C and D). Confocal Z-stack imaging showed that claudin-3 protein was localized with particularly high abundance at the hepatocyte canalicular membrane (Figure 1E and Supplementary Video 1) and had strong expression on the luminal membranes of cholangiocytes (Figure 1F). By immunofluorescence, we observed that claudin-3 protein has a zonated expression pattern in the liver, with the highest staining intensity in the pericentral region (Figure 1G). In summary, our scRNA-seq and immunofluorescence data show that claudin-3 is a prominent hepatic TJ protein that is found predominantly on canalicular membranes of pericentral hepatocytes and on the membranes of ductal cholangiocytes.

Effect of Claudin-3 Deletion on Liver Histology and TJ Integrity

We next assessed if claudin-3 contributes to normal liver homeostasis and function by studying mice with global claudin-3 knockout. We first verified that Cldn3−/− mice had no claudin-3 protein expression and confirmed the specificity of the claudin-3 antibody by Western blot and by immunostaining of liver tissue (Figure 2A and B). The livers of Cldn3−/− mice had no macroscopic anatomic abnormalities (Figure 2C) and the liver’s histology was unremarkable compared with age-matched littermate controls (Figure 2D). Furthermore, we could not detect gaps or discontinuations at TJs by electron microscopy (Figure 2E). There was also no difference in collagen deposition in male compared with female Cldn3−/− livers (Figure 2F and G). Serum analysis showed no difference in alanine aminotransferase (ALT)
Figure 1. Cell type–specific analysis of TJ gene expression in a native mouse liver shows high expression of claudin-3 in hepatocytes and cholangiocytes. (A) Unsupervised clustering of the scRNA-seq data used for cell classification. (B) t-Distributed stochastic neighbor embedding (tSNE) plots depicting the expression of marker genes to define different hepatic cell populations: hepatocytes (HC), cholangiocytes (CC), stellate cells (SC), immune cells (IC), endothelial cells (EC). (C) Heatmap of scRNA-seq data depicting cell type–specific expression of hepatic TJ genes. Expression was normalized by cell type. (D) tSNE plot depicting the expression of Cldn3. (E) Three-dimensional reconstruction of a 30-µm–thick confocal z-stack section stained for claudin-3 immunofluorescence (green), DAPI (blue) in mouse liver tissue. (F) Anti-claudin-3 centered on a bile duct. (G) Lower-magnification image showing zonated claudin-3 expression in the murine liver. (E–G) The microscope used for fluorescent image acquisition was a panoramic 250 Flash III, 3DHISTECH, panoramic scanner software, with a 40× objective. BC, bile canaliculus; BD, bile duct; NE, normalized expression; PC, pericentral zone; PP, periportal zone.
and aspartate aminotransferase (AST) levels, but slightly higher levels of alkaline phosphatase (ALP) in Cldn3–/– livers, with 142.3 ± 15.8 U/L compared with 117.8 ± 23.3 U/L in Cldn3+/+ livers (Figure 2H). It has been described that loss of TJ integrity may cause inflammation and ductular reactions as a result of the cytotoxic effect of bile acid leakage.28 Confirming our observation of intact TJ structures in Cldn3–/– livers, we did not observe an increase in cytoplasmic keratin 7 (CK7), a marker for ductular reactions (Figure 2I and J) or an increase in the frequency of innate or adaptive immune cells in the livers (Figure 2K). In summary, we did not observe any gross alterations in liver histology or signs of loss of TJ integrity in Cldn3–/– mice.

**Claudin-3 Deletion Represses Metabolism and Bile Synthesis Gene Expression**

Questioning the absence of an overt phenotype by loss of claudin-3, we next checked if there were any overall changes in gene expression in Cldn3–/– livers. RNA-seq analysis showed that there were 705 differentially expressed genes between wild-type and Cldn3–/– livers, of which 337 genes were up-regulated, and 368 genes were down-regulated (Figure 3A). Genes related to cell adhesion and cell junctions were up-regulated significantly in Cldn3–/– livers, for example, there was higher expression of Ocln (Ocludin), Tricellulin (Marveld2), Cldn7, Cldn23, and Cgn (Figure 3A and B). The most important changes were verified by comparative real-time quantitative polymerase chain reaction (qPCR) (Figure 3D). From the RNA-seq data, we also observed a significant down-regulation of genes and pathways related to metabolism, including fatty acid-, amino acid-, bile acid-, and lipid-related gene expression in Cldn3–/– livers (Figure 3A and C). This observation was consistent with the low amount of lipid droplets in Cldn3–/– hepatocytes, as seen by electron microscopic and quantified Oil-red-O staining (Figure 3E–G). We next questioned the possible cause for repressed lipid metabolism in Cldn3–/– livers. Glucose is one of the main drivers of de novo lipogenesis in the liver, which requires its efficient absorption in the intestine.29 Because past reports have shown that claudin-3 also is expressed in the intestine,24 we hypothesized that an inefficient baseline glucose absorption within the intestine may explain the down-regulation in lipid metabolism in Cldn3–/– mice. However, baseline blood glucose levels did not differ significantly, and Cldn3–/– mice showed a similar absorption and clearance after oral glucose challenge (2 mg/g bodyweight) when compared with Cldn3+/+ mice (Figure 3H). Accordingly, serum insulin levels were not significantly different between Cldn3+/+ and Cldn3–/– in the oral glucose tolerance test (Figure 3I). Taken together, we observed many deregulated genes in Cldn3–/– livers, including a compensatory increase of TJ gene expression and a repressive effect on metabolic processes in the liver.

**Effect of Claudin-3 Deletion in Aged Animals**

Because we observed a repression of lipid metabolism in Cldn3–/– mice, we next questioned how they respond to the metabolic challenge of aging. It has been well described that senescence-related events that come with advanced age lead to increased accumulation of lipids and triglycerides in the liver.30-32 We first compared liver tissue of 12-week-old and 52-week-old mice and did not observe a change in hepatic claudin-3 protein levels resulting from age (Figure 4A). The bodyweight of Cldn3+/+ vs Cldn3–/– mice was similar over time, while the liver-to-weight ratio of 52-week-old Cldn3–/– mice was slightly higher (Figure 4B and C). Liver damage markers ALT and AST did not differ (Figure 4D), however, we observed the same trend of increased ALP in aged Cldn3–/– that was present in young animals (Figures 4D and 2H). In aged mice, there was no difference in collagen deposition owing to loss of claudin-3 expression (Figure 4E). We next compared the transcriptomic profile of young vs aged Cldn+/+ and Cldn3–/– mice by RNA-seq. In young animals there were differences owing to the loss of claudin-3 expression, however, the metabolic challenge of age was stronger than the effect of the loss of claudin-3 in aged animals (Figure 4F). Analysis of differentially expressed genes showed that in both Cldn3+/+ and Cldn3–/– aged animals there was a profound down-regulation of metabolic pathways including fatty acid metabolism and

---

**Figure 2. (See previous page). Effect of claudin-3 loss on liver morphology and TJ structure integrity.** Mice with global claudin-3 knockout were generated as described in the Methods section. (A) Anti–claudin-3 Western blot on whole-liver tissue lysates of Cldn3+/+ and Cldn3–/– mice. β-actin for loading control. No claudin-3 was detected in Cldn3–/– samples, and only a single specific band was seen in Cldn3+/+ mice (n = 9). (B) Anti–claudin-3 immunofluorescence (green; DAPI in blue), and immunohistochemistry in Cldn3+/+ and Cldn3–/– liver tissue. Claudin-3 staining was absent in the Cldn3–/– samples. (C) Photographs of native Cldn3+/+ and Cldn3–/– livers. (D) H&E staining. (E) Transmission electron microscopy (TEM) images centered on bile canaliculi. (F and G) Masson trichrome staining of female and male liver tissue. (H) Serum AST, ALT, and ALP levels in Cldn3+/+ vs Cldn3–/– mice (n = 10, means ± SD, *P < .05, unpaired t test). (I) Anti-CK7 Western blot on whole-liver tissue of native Cldn3+/+ and Cldn3–/– mice. Band intensities were normalized to β-actin (n = 5, t test, Cldn3+/+ band intensities were compared with their group average). (J) Anti-CK7 immunofluorescence (red) in perportal liver tissue, and DAPI in blue. Representative images were taken. Quantification of the Western blot below (n = 5, bars represent means ± SEM, unpaired t test). (K) Fluorescence-activated cell sorting analysis of innate and adaptive immune cell populations. The frequency of immune cells was not different in Cldn3+/+ and Cldn3–/– native livers (n = 5, unpaired t test). The microscopes used for image acquisition in this figure were an immunofluorescence Leica DMI4000B with a 20× objective with Leica advance fluorescence software, and an immunohistochemistry panonomic 250 Flash III, 3DHISTECH, panonomic scanner software, with a 20× objective; electron microscopy, Philips CM 12. BC, bile canalculus; CK7, cytokeratine 7; ILC, innate lymphoid cells; Inflam. Mono., inflammatory monocytes; NK, natural killer cells; NK-T, natural killer T-cells; PC, pericentral area; PP, perportal area.
catabolic processes and an up-regulation of inflammation and immune responses (Figure 4G and H). However, when aged Cldn3−/− and Cldn3+/− were compared, only a few genes were significantly different, particularly Apol9a, Apol9b, and Cyp26a1, genes related to cholesterol and lipid metabolism, which were lower in Cldn3−/− mice (Figure 4I).

Following results from our RNA-seq data and reports that age leads to impaired lipid metabolism,30–33 we were able to confirm a significant increase of lipid content in aged livers, however, Cldn3+/− mice had a lower lipid content compared with Cldn3−/− mice (Figure 4J) as we observed previously in young animals (Figure 3E–G). For further validation of the inflammatory phenotype that our gene expression data indicated (Figure 4G and H), we showed that the frequency of total hepatic lymphocytes increased with age in both groups (Figure 4K). In summary, all aged animals had higher amounts of hepatic lipids and liver inflammation compared with young animals, and aged Cldn3−/− mice retained lower hepatic lipid levels compared with wild-type controls.

**Impairment of the Blood-Biliary Barrier in Cldn3−/− Livers**

Our RNA-seq analysis showed that genes involved in bile acid metabolism such as Cyp27a1, Ces1b, and Akr1c6 were down-regulated in Cldn3−/− mice (Figure 3A). We therefore questioned if there are lower bile acid levels in Cldn3−/− mice by measuring their abundance in liver tissue and serum by liquid chromatography–tandem mass spectrometry. Lower total bile acid levels were measured in the liver tissue, while total bile acids were higher in the serum of Cldn3−/− mice compared with Cldn3+/− mice (Figure 5A and B). The proportion of primary bile acids was higher in the serum of Cldn3−/− mice (Figure 5B). Importantly, individual bile acids were significantly less concentrated in the liver (Figure 5C), and more highly concentrated in the serum (Figure 5D). This included cholic acid (CA), taurocholic acid (TCA), taurochenodeoxycholic acid, conjugated forms of muricholic acids and the secondary bile acid tauro-7-oxolithocholic acid (Figure 5C and D). The other individual bile acids did not significantly differ between Cldn3+/− and Cldn3−/− in the liver or serum (Figure 5E and F). The change in bile composition prompted us to check the appearance of the gallbladders. We did not find any incidence of gallstones in the gallbladders and observed that Cldn3−/− gallbladders were lighter in color compared with wild-type organs (Figure 6A). As a possible contributing factor to the change in circulating bile acid composition, we checked in the RNA-seq data if the expression of transporters is altered in Cldn3−/− mice (Figure 6B). The expression of transporter transcripts that showed a trend in the RNA-seq results were verified by real-time qPCR (Figure 6C). We observed higher expression of Ost1-β (Slc51b), and a trend for higher Asbt (Slc10a2) levels in Cldn3−/− mice (Figure 6B and C). Because the nuclear transcription factor Farnesoid X-receptor is a regulator of bile transporters,33 we checked Fxr and downstream target expression (Figure 6D). However, we found only a modest alteration of the Farnesoid X-receptor targets Bacs (Slc27a5) and Apoa1 (Figure 6D). Finally, we tested the expression of Fgfl5 in the ileum (Figure 6E), but did not observe a difference in Cldn3−/− when compared with Cldn3+/− animals. In conclusion, our results suggest that the biliary barrier of Cldn3−/− mice is partially impaired and alterations in bile acid transporter expression also may contribute to the change in hepatic bile acid levels.

**Hepatic Proliferation Is Impaired in Cldn3−/− Mice After Partial Hepatectomy**

The observations that loss of claudin-3 expression affects liver metabolism, particularly lipid metabolism and hepatic bile acid content, raised the question of whether claudin-3 is important for the liver’s response to injury. Therefore, we tested if the loss of claudin-3 expression altered the liver’s ability to regenerate after PHx. We observed a time-dependent regulation of claudin-3 mRNA and protein in wild-type animals in response to PHx. Cldn3 expression was decreased after 3 and 6 hours and increased above baseline levels starting at 24 hours (Figure 7A). We validated this observation by immunofluorescent staining (Figure 7B) and Western blot (Figure 7C and D). The zonated expression pattern that was present in native liver tissue was lost at 48 hours after PHx (Figure 7B). PHx leads to...
to high pressure and mechanical stress within the first hours after resection, therefore, we checked if the increased stress affected the integrity of TJs in *Cldn3*−/− mice. However, by electron microscopy, we did not find any gaps or other obvious membrane impairments after 6 hours after PHx in either *Cldn3*+/− or *Cldn3*−/− (Figure 7E). In agreement, there were no signs of an inflammatory reaction based on cytokine secretion or cytokeratine expression (Figure 7F–H), and the frequencies of immune cells were not significantly different in regenerating *Cldn3*−/− livers (Figure 7I).

We next determined the proliferative scores 48 hours after PHx. The percentage of Ki67-positive hepatocytes was 76% ± 4% in *Cldn3*+/+ mice compared with 49% ± 5% in *Cldn3*−/− mice (P < .01) (Figure 8A). For the mitosis marker phosphohistone H3 (pHH3), *Cldn3*+/+ livers had 32% ± 3% pHH3-positive nuclei, compared with only 15% ± 1% in *Cldn3*−/− livers (P < .01) (Figure 8B). Supporting these results, the transcription of Foxm1 increased 43- ± 3-fold over controls in *Cldn3*+/+, and only 16- ± 2-fold in *Cldn3*−/− livers (P < .001) (Figure 8C). Similarly, Ccnb1 and Birc5 were significantly less transcribed in *Cldn3*−/− mice at 48 hours after PHx. The proliferation inhibitor p21 (Cdkn1a), on the other hand, was expressed higher in *Cldn3*−/− mice at 24 and 48 hours after PHx (P < .05 and P < .01, respectively) (Figure 8C). At 72 hours after PHx, the proliferation scores and the expression of genes regulating cell proliferation did not differ between *Cldn3*+/+ and *Cldn3*−/− mice. RNA-seq data of liver tissue 48 hours after PHx supported the immunofluorescense and real-time qPCR data (Figure 8D). Genes associated with cell division, cell-cycle regulation, cholesterol synthesis, and glucose metabolism were expressed at a lower level in regenerating *Cldn3*−/− livers (Figure 8D and F), whereas genes related to circadian rhythm, negative regulation of metabolism, lipid catabolism, and calcium ion binding, as well as others, were found to be up-regulated (Figure 8D and E). Taken together, we saw that *Cldn3*−/− mice had an impairment in proliferation after PHx.

**Discussion**

Several studies have described hepatic TJ proteins and their function within the blood-biliary barrier.4,14,16,18,22 By using scRNA-seq, we expanded the available information on hepatic TJ gene expression by describing their abundance in the various cell populations of the liver. We found the expected expression pattern for some genes, for example, *Cldn1, Cldn2, Cldn5, and Cldn7*, and, interestingly, we observed expression of *Cldn5, Jam-a, Jam-b, Afox, Sympk,* and Ybx3 in stellate and immune cells, suggesting a role of TJ genes outside the blood-biliary barrier. Our scRNA-seq data support that *Cldn3* is one of the most highly expressed TJ genes in the mouse liver with its mRNA and protein expressed predominantly in hepatocytes and cholangiocytes.16,22,40,42 Within a liver lobule, there is a discernable metabolic zonation,43,44 and bile acid synthesis is highest in the first 3 hepatocyte cell layers around the central veins.45 This correlates with the high level claudin-3 expression we observed in the pericentral region, suggesting that the liver may express higher levels of claudin-3 to ensure a tightly sealed blood-biliary barrier in the location of higher bile acid concentrations.

To study the consequence of loss of claudin-3 expression, we used *Cldn3*+/− mice, however, the phenotype we observed was milder than what was reported originally.22 For example, in our study, there was a very moderate increase of total serum bile acids and no gallstones were found even in aged animals.22 A possible explanation could be differences in environmental factors such as nutrition or microbiota.46 Our transmission electron microscopy images support that hepatic TJs in *Cldn3*−/− mice are intact because the membranes of adjacent cells are tightly sealed.22

---

**Figure 4. (See previous page).** Metabolic challenging by aging leads to lower lipid accumulation in *Cldn3*−/− liver. (A) Anti-claudin-3 Western blot on whole-liver tissue lysate of young (12 weeks) and aged (52 weeks) wild-type mouse livers. β-actin was used as loading control (n = 5). (B) Body weight measurements in *Cldn3*+/− (gray line) vs *Cldn3*−/− (black line) mice at the indicated age of life (12 weeks, n = 7 [Cldn3+/+] and n = 11 [Cldn3−/−]; 13 weeks, n = 6 [Cldn3+/+] and n = 4 [Cldn3−/−]; 15 weeks, n = 5 [Cldn3+/+] and n = 7 [Cldn3−/−], 22–24 weeks, n = 5; 39 weeks, n = 3 [Cldn3+/+] and n = 4 [Cldn3−/−], 52 weeks, n = 3 [Cldn3+/+] and n = 5 [Cldn3−/−]). No significant differences were observed at any age (unpaired t test). (C) Liver-to-bodyweight ratio was measured (12 weeks, n = 7 [Cldn3+/+] and n = 11 [Cldn3−/−]; 13 weeks, n = 6 [Cldn3+/+] and n = 4 [Cldn3−/−]; 15 weeks, n = 5 [Cldn3+/+] and n = 6 [Cldn3−/−]; 22–24 weeks, n = 5; 39 weeks, n = 3 [Cldn3+/+] and n = 4 [Cldn3−/−]; 39 weeks, n = 3; 52 weeks, n = 3 [Cldn3+/+] and n = 5 [Cldn3−/−]; *P < .05*, unpaired t test). (D) Serum AST, ALT, and ALP levels in mice 1 to 2 years old. *Cldn3* vs *Cldn3*−/− mice (n = 11 for *Cldn3*+/+ and n = 18 for *Cldn3*−/−, means ± SD, *P < .05*, unpaired t test). (E) Masson trichrome staining in aged mice. Representative image is shown (n = 3 and n = 4 for *Cldn3*+/+ and *Cldn3*−/−, respectively). (F) Principal component analysis plot based on RNA-seq gene expression data of aged (*circles*) and young (diamonds) *Cldn3*+/− (blue) and *Cldn3*−/− (red) mice (n = 3 for both aged groups, n = 3 for young *Cldn3*+/+ and n = 4 for young *Cldn3*−/− group). (G and H) Volcano plots and metascape analysis showing up-regulated and down-regulated genes and the top 10 up-regulated and down-regulated pathways in young (12 weeks) and aged (1.5–2 years) (G) C57BL/6 J mice and (H) *Cldn3*−/− mice. RNA-seq analysis was performed by DESeq2 (n = 3 for both aged groups, n = 3 for young *Cldn3*+/+ and n = 4 for young *Cldn3*−/− group, differential expression significance threshold: P value adjusted < .05). Genes or pathways with low expression in aged mice are shown in blue, and with high expression in aged mice are shown in red. (I) Volcano plot showing differential gene expression in aged *Cldn3*+/+ vs aged *Cldn3*−/− mice, with regulated genes annotated next to it. Parameters of the differential gene expression as shown in panels G and H. (J) Oil-red-O staining on liver tissue sections. Quantification of images from randomly chosen regions below (n = 6, bars represent means ± SD, unpaired t test). (K) Fluorescence-activated cell sorting analysis comparing young and aged *Cldn3*+/+ and *Cldn3*−/− mice (n = 4 in young, n = 3 in aged *Cldn3*+/+ and n = 5 in aged *Cldn3*−/−, unpaired t test, *P < .05, *P < .01). Microscopes used for image acquisition in this figure: Masson trichrome staining and Oil-red-O staining, panoramic 250 Flash III, 3DHiSTech, panoramic scanner software, with a 40× objective. KO, knockout; PC, pericentral; WT, wild-type.
Consequently, we could not detect morphologic changes or signs of inflammation or fibrosis owing to loss of claudin-3 expression. This lack of phenotype may be explained by the higher expression of other TJ-forming genes such as occludin and tricellulin, which may have functionally compensated for the loss of claudin-3.

However, by sequencing the livers of Cldn3/fl mice we found significant repression in hepatic metabolism. There was a lower amount of lipid droplets in Cldn3/fl livers and down-regulation of key genes related to lipogenesis including Srebf1. A main activator of SREBF1 and its downstream targets is glucose. We therefore tested if glucose uptake and insulin secretion are affected in Cldn3/fl mice, which was not the case. However, we observed decreased expression of bile acid synthesis–involved genes including Cyp27a1 and Akr1c6. In combination with the changed composition of the circulating bile acid pool in Cldn3/fl mice, it is possible that altered bile metabolism negatively influenced the energy metabolism of the liver, because bile acids are important regulators of lipogenesis. The altered lipid metabolism in Cldn3/fl prompted us to question how the mice respond to a metabolic challenge, which we induced by letting the mice age for up to 2 years. Of note, we did not observe a decrease in expression of claudin-3 protein in aged wild-type mice, as previously suggested. In aged livers, we observed the expected accumulation of hepatic lipids as well as inflammation and immune cell infiltrations. These events took place in Cldn3/fl mice as well. When comparing the gene expression in aged Cldn3/+ vs aged Cldn3/fl/+ mice by RNA-seq, we found a lower expression of lipid metabolism–related genes Apol9a/b and Cyp26a1 in the knockout animals. In conjunction, we also observed a lower amount of lipids in aged Cldn3/fl compared with aged Cldn3/fl/+ liver. This implies that Cldn3/fl mice respond differently to the metabolic challenge of age, accumulating fewer hepatic lipids. Both Cldn3/fl/+ and Cldn3/fl mice showed a high lipid and inflammatory phenotype upon metabolic challenge by age, however, aged Cldn3/fl mice again showed a phenotype of repressed lipid metabolism.

Because our differential gene expression data showed repression of bile acid synthesis–involved genes including Cyp27a1 and Akr1c6, we also questioned if the composition of bile acids differs in Cldn3/fl mice. Our results showed that Cldn3/fl mice have a reduction in the concentration of hepatic CA, and its conjugated form TCA. In contrast, serum levels of TCA were higher in Cldn3/fl mice, and there was a trend toward higher CA serum levels. Similarly, conjugated subtypes of a mouse-specific bile acid, muricholic acid, were decreased in the Cldn3/fl liver, and increased in the serum. The cause for the higher amount of serum bile acids could be owing to leaks of TJ barrier that are not visible by electron microscopy, or were owing to the slightly higher expression of the biliary exporter Osl1-β. Because bile acids are important for efficient nutrient digestion and lipid uptake, we may speculate that the change in bile acid composition was a contributing factor to the repression in lipid metabolism of Cldn3/fl livers. We next questioned whether the alterations in lipid metabolism and biliary barrier influenced the ability of the liver to regenerate. In fact, both efficient lipid supply and bile acid accumulation are required to settle the increased energy demand of hepatocytes during cell division. Interestingly, we observed an up-regulation of claudin-3 expression between 24 and 48 hours after PHx, which is in agreement with previous observations made in rats. The increase of claudin-3 expression suggests that the biliary barrier needs to be tightened at this particular time after surgery. Possibly, claudin-3 retains bile acids to prevent hepatocellular damage, and/or to keep bile acids as liver regeneration–promoting signals. Our results showed that cell proliferation was decreased significantly in regenerating Cldn3/fl livers, with approximately one-third less Ki67-positive and only half the amount of PHH3-positive cells at 48 hours after PHx. Because liver regeneration has high clinical relevance for treatment of hepatic malignancies and the repair of trauma, our results might be of interest for further investigations on the role of TJ proteins for optimal recovery after tissue loss.

Taken together, our data suggest that loss of claudin-3 leads to an impairment in lipid metabolism and an impaired biliary barrier in mice. Both of these phenotypes likely contribute to the suboptimal hepatic proliferation after PHx. However, we cannot exclude the possibility that claudin-3 is associated with signaling pathways that regulate the cell cycle. For example, claudin-3 is in direct and indirect contact with TJ adapter proteins that are upstream of transcription factors, including zonula occludens 1 (ZO-1)-associated nucleic acid binding protein (ZONAB), cellular myelocytomatosis protein (C-MYC), β-catenin, yes-associated protein 1 (YAP), and others. It will be of future interest to investigate the potential role of claudin-3 in the context of signaling pathways that control cell proliferation.

### Materials and Methods

#### Generation of Cldn3/fl Mice

We described the generation of this strain with global claudin-3 knockout in detail in a previous publication. In Figure 5. (See previous page). Partial impairment of the Cldn3/fl biliary barrier alters bile acid homeostasis. (A) Liquid chromatography–mass spectrometry (LC-MS) analysis of liver bile acids (n = 12/Cldn3/fl/+ and n = 11/Cldn3/fl, means ± SEM, unpaired t test). (B) LC-MS analysis of serum bile acids (n = 11, means ± SEM, *P < .05, unpaired t test). (C) LC-MS analysis showing individual bile acid types in the liver (n = 12/Cldn3/fl/+ and n = 11/Cldn3/fl, means ± SD, *P < .05, **P < .01 Mann–Whitney test). (D) LC-MS analysis showing individual bile acid types in the serum (n = 11, means ± SD, *P < .05, **P < .01 Mann–Whitney test). (E and F) Bile acids that were not changed significantly in Cldn3/fl/+ vs Cldn3/fl liver tissue or serum (n = 11, means ± SD, Mann–Whitney test). CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GCA, glycocholic acid; UDCA, ursodeoxycholic acid; GUDCA, glycurso deoxycholic acid; HDCA, hyodeoxycholic acid; MCA, muricholic acid; oxoLCA, o xo-lithocholic acid; TCDCA, taurohydoxycholic acid; TDCDA, tauro-deoxycholic acid; TLCA, tauro-lithocholic acid; TUDCA, tauro-ursodeoxycholic acid; UDCA, ursodeoxycholic acid.
animal stem cells, we used a PGK neo cassette to replace most of the claudin-3 coding region, except for the last 30 nucleotides of the open reading frame. This created a knockout allele and prevented claudin-3 peptide formation, which we confirmed by Western blot and immunofluorescence (Figure 2A and B). By interbreeding heterozygous parents, we created homozygous Cldn3−/− mice at almost Mendelian ratios (23.5%). To homogenize the C57BL/6J genetic background, we backcrossed for more than 10 generations.

Animal Housing and PHx Surgery
Both experimental C57BL/6 Cldn3−/− and control C57BL/6J Cldn3−/−/+ mice were born and raised within the same animal housing facility. Mice were housed under specific pathogen-free conditions at 22°C, 55% relative humidity, with free access to Chow and water, and in a 12-hour, light-cycle controlled room. Green Line individually vented cages (Tecniplast, Hohenpeissenberg, Germany) were used at positive pressure. Safe Aspen (S-Aspen-09322; JRS, Horn, Switzerland) cage bedding was used. Animal cages contained enrichment and activation tools such as plastic mouse house (Tecniplast), Nestlet or Sizzle nests (Plexx, Eist, Netherlands), and Pura Crinkle Brown Kraft Paper (Labodia, Niederglatt, Switzerland). Mice were fed a standard dry pellet cereal-based diet (10343200PXV20; Granovit, Switzerland). Interventions were performed during the dark dry pellet cereal-based diet (10343200PXV20; Granovit, Switzerland). Mice were killed by exsanguination under deep anesthesia. All mouse experiments were performed with the approval of the Veterinary Office of the Canton Bern (permit BE51/18), according to the guidelines of good animal practice as defined by the Office of Laboratory Animal Welfare, and adhering to the standards of the national centre for the replacement refinement and reduction of animals in research guidelines (https://www.nc3rs.org.uk/arrive-guidelines).

Single-Cell RNA Sequencing

The unique molecular identifiers (UMI) matrix of our recently published scRNA-seq was downloaded (GEO accession number: GSE134134).26 We removed cells with more than 15% UMIs coming from mitochondrial genes and cells with more than 25% UMIs coming from globin genes. In addition, a cell containing an abnormally high number of UMIs (110,270) was excluded. Next, we removed genes that were not expressing at least 2 reads in 2 genes. After data preprocessing, the UMI matrix was processed as previously described.26 Shortly, we transformed the UMI matrix into a Seurat object (Paul Hoffman, Satija Lab, New York Genome Center, New York) with Seurat 2 (PMID: 31178118). The data of the Seurat object were log-normalized, the variable genes were identified, and the data were scaled. Next, we computed the principal component analysis with the R (RStudio PBC, Boston, MA) function RunPCA, we identified the clusters with the R function FindClusters with dims.1. resolution=1. Finally, we computed the t-distributed stochastic neighbor embedding coordinates with the R function RunTSNE with dims.use=1.8.

Cell identification. In Figure 1B, we show the expression of the following cell population markers (Figure 1B shows markers): hepatocytes: Alb (shown), Apoa1, G6pc, Hnf4a, Asgr1, Mup3, Pck1; cholangiocytes: Krt7 (shown), Krt19, Muc1, St14; endothelial cells: Pecam1 (shown), Dpp4, Oit3, Gpr182, Lyve1, Ushbp1, Tek; stellate cells: Des (shown), Reln, Rbp1, Prnp, Vcl, Hhip, Col1A1; and immune cells: Ptprc (Cd45) (shown). Based on clustering and gene expression, we defined cluster 9 as hepatocytes; cluster 7 as cholangiocytes; clusters 2, 4, 5, 8, 11, and 12 as immune cells; clusters 0, 1, 3, 10, and 13 as endothelial cells; and cluster 6 as stellate cells (Figure 1A).

Data visualization. To display the gene expression, the preprocessed UMI matrix was normalized with the function library.size.normalization of the R package magic.

The dropout correction was performed with the R function magic with parameters genes=“all_genes”. The dropout corrected data were displayed on the t-distributed stochastic neighbor embedding plots.

Heatmap. The unsupervised clusters containing the same cell types were merged and we averaged the UMI expression in each cell type, the average expression of each gene was normalized from 0 to 1, f(x) = (x-min(x))/(max(x)-min(x)), and represented as a heatmap with the R package gplots.

Histology

Immunohistochemistry and immunofluorescence. Paraffin-embedded liver tissue was sectioned at a thickness of 6 µm for conventional imaging or 30 µm for confocal z-stack imaging. Slides were deparaffinized and hydrated in a xylol and ethanol series. For nuclear staining, membrane permeabilization was performed by 20-minute incubation in phosphate-buffered saline (PBS)–Triton X-100 (0.4%) (1.09468.0100 and 108603; Mercck, Darmstadt, Germany).

Antigen retrieval was performed by heat-induced epitope retrieval for 10 minutes at 95°C in citrate buffer, pH 6.0 (C9999; Sigma-Aldrich, Buchs, Switzerland). Nonspecific antibody binding was blocked at room

Figure 6. (See previous page). Loss of claudin-3 increases hepatic expression of the bile acid transporter Ost1-β. (A) Photographs of Cldn3−/+ and Cldn3−/− gallbladders (n = 7). (B) RNA-seq data showing expression of bile transporters (n = 3, mean ± SD, *P < 0.05, unpaired t-test). (C) Comparative real-time qPCR determining the transcriptional levels of hepatic Ost1-β (Scl51b), Asbt (Scl10a2), and Mdr3 (Abcb4) (n = 6, mean ± SD, *P < 0.05, unpaired t-test). (D) RNA-seq data showing hepatic expression of Fxr and its downstream targets (n = 3, mean ± SD, *P < 0.05, unpaired t-test). (E) Comparative real-time qPCR determining the transcriptional levels of Fgtf15 in the ileum (n = 5 for Cldn3−/+ and n = 9 for Cldn3−/−, mean ± SD, unpaired t-test). FXR, farnesoid X-receptor; NE, not expressed.
temperature for 1 hour using a protein-blocking solution (X0909; Dako, Santa Clara, CA). Antibodies were prepared in antibody diluent (S3022; Dako) at the following dilutions. Primary antibodies were as follows: Ki67 (RM-9106-S1, 1:300; Thermo Fisher Scientific, Basel, Switzerland); anti-phospho-histone H3 (06-570, 1:250; Merck Millipore, Burlington, MA); claudin-3 (NBPI-35668, 1:50; Novus Biologicals, Littleton, CO); and cytokeratin 7 (NBPI-88080, 1:200; Novus Biologicals). Secondary antibodies were as follows: anti-rabbit-Cy5 (A10523, 1:300; Fisher Scientific, Waltham, MA); anti-mouse Alexa 488 (A-11001, 1:300; Fisher Scientific); and polyclonal rabbit anti-goat immunoglobulins/horseradish peroxidase (P0449; Dako). For the development of immunohistochemistry staining, streptavidin-peroxidase (71-00-38; BioConcept, Allschwil, Switzerland) and 3',3'-diaminobenzidine tetra hydrochloride (D4293-50SET; Sigma-Aldrich) were used. Primary antibodies were incubated with gentle agitation inside a wet chamber overnight at 4°C. Slides were washed for 20 minutes in PBS-Tween-20 (0.5%), P1379; Sigma-Aldrich) and incubated in darkness for 90 minutes with the secondary antibodies and 4',6-diamidino-2-phenylindole (DAPI) (D9542, diluted 1:2000; Sigma-Aldrich). After a final wash in PBS-Tween-20 (0.5%), slides were mounted with fluorescence mounting medium (H-1000; Vectorlabs, Burlingame, CA) and the coverslip was fixed with nail polish. For immunohistochemistry staining, erythrocytes were lysed in 5% H2O2 for 10 minutes before the first antibody incubation, and the staining was developed after the secondary antibody application by incubation with streptavidin-peroxidase for 30 minutes and 3',3'-diaminobenzidine tetra hydrochloride for 1 minute. Representative images that were selected for display in the publication were moderately adjusted in brightness and color intensity with the help of image editing software. Importantly, adjustments were always made in the same way for all samples.

For image acquisition, sections with 6-μm or 10-μm thickness were imaged using a fluorescent and bright-field microscope (panoramic 250 Flash III, panoramic scanner software, 3DHISTECH, Budapest, Hungary). Sections (30 μm) were imaged with a confocal microscope (LSM 710; Zeiss, Oberkochen, Germany), and 3-dimensional reconstructions from z-stack images were made using the Zeiss Zen software (Black edition, release version 8.1). Quantification of staining intensity and automated counting of Ki67+/pH3-positive nuclei was performed exclusively on unmodified raw images.

**H&E staining.** Liver paraffin sections were stained with hematoxylin (HX43078349; Merck) for 6 minutes and differentiated in hydrochloric acid: ethanol (1:1) performing 3 dips. Slides were incubated in eosin (45240; Fluka Chemical Corp, Charlotte, NC) for 3 minutes, followed by dehydration and mounting with Eukitt (Kindler, Freiburg im Breisgau, Germany).

Hepatic proliferation was quantified by imaging of 4 randomly chosen regions per liver, containing approximately 1000 DAPI-positive nuclei per region. Ki67- and pH3-positive nuclei were counted and normalized as the percentage of all DAPI-positive cells with the help of ImageJ software (version 1.48; National Institutes of Health, Bethesda, MD).

**Oil-red-O staining and quantification.** Liver tissue was embedded in Tissue-Tek O.C.T. medium (4583; Sakura Finetek, Staufen im Breisgau, Germany), and 5-μm crossections were cut (CM3050S Cryostat; Leica, Wetzlar, Germany). Slides subsequently were stained with Oil-Red-O (00625; Sigma-Aldrich): frozen sections were brought to room temperature, rinsed briefly in 60% triethyl phosphate (538728; Sigma-Aldrich), and subsequently stained in 0.5% Oil-red-O for 20 minutes. After a wash in distilled water, sections were counterstained in filtered hematoxylin (HX43078349; Merck, Dietikon, Germany) for 90 seconds, and nuclei were blued in saturated lithium carbonate (1.05680.0250; VWR, Dietikon, Switzerland) for 15 seconds. Slides then were rinsed with a flow of water for 5 minutes and mounted with glycerin jelly.

For staining quantification, a method based on previously published quantification techniques was used.69,70 The image analyzing software Fiji was used.71 Magnified images (40 ×) with areas of the exact same

---

**Figure 7.** (See previous page). **Clcn3 expression is regulated after PHx and claudin-3 loss does not induce inflammation in regenerating livers.** Comparative real-time qPCR determining the transcriptional levels of Cldn3 during a 7-day time course after PHx (n = 3, **P** < .01, unpaired t test). (B) Anti-claudin-3 immunofluorescent stainings (green) in liver after PHx, and DAPI in blue. Representative images were taken. (C) Liver tissue Western blot for claudin-3 (20 kilodaltons) and β-actin (42 kilodaltons) at the indicated time points after PHx (n = 3/0–6 h, n = 4/0–24 h, n = 4/0–48 h). (D) Quantification of the Western blot in panel C. (E) Transmission electron microscopy images in liver tissue 6 hours after PHx. Arrowheads point to intact TJJs located at Clcn3-/- and Clnd3-/- bile canaliculi (BC). (F and G) Quantification of ductular reaction in liver tissue. Total liver protein was isolated after PHx and used for anti-CCK7 Western blot. Band intensities were normalized to β-actin.

Expression of hepatic CK7 was similar in Clcn3-/- and Clnd3-/- mice (n = 5, unpaired t test, Clcn3-/-, band intensities were compared with their group average). (H) Serum cytokine levels 48 hours after PHx. With the exception of a slightly decreased MIP1α concentration in Clcn3-/- mice, there were no significant differences comparing the groups (n = 7 for Clcn3-/- and n = 6 for Clnd3-/-; means ± SEM, **P** < .05, unpaired t test). (I) Fluorescence-activated cell sorting analysis of hepatic immune cell frequencies at the indicated times after PHx. By a slightly higher B-cell frequency at 24 hours in Clnd3-/- mice, there were no significant differences compared with Clcn3-/- mice (at 0 h and 24 h: n = 5 for Clcn3-/- and n = 4 for Clnd3-/-; 48 h, n = 5; 72 h, n = 8; unpaired t test). Microscopes used for image acquisition in this figure were as follows: immune fluorescence, panomatic 250 Flash III, 3DHISTECH, panoramic scanner software, with a 20× objective; electron microscopy, Philips CM 12. CK7, cytokeratine 7; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFNγ, interferon γ; IL, interleukin; LIF, leukemia inhibitory factor; MIP1α, macrophage inflammatory protein α; NK, natural killer cells; NKT, natural killer T-cells; PC, pericentral; PP, perportal; TNF-α, tumor necrosis factor α.
sizes of 4 randomly chosen areas per sample were taken. Color deconvolution was performed (with the pre-set “H AEC”) to separate the hematoxylin and the Oil-red-O staining. The lipid droplet contained in the red channel was selected, and the threshold was adjusted to the same level for each image (values, 0 and 200). The threshold-adjusted image then was converted to a black-and-white 8-bit image (“apply”). The intensity of the staining then was measured with the analyze -> measure option. Staining intensities are given as integrated density.

**Masson trichrome staining.** Paraffin-embedded liver tissue was dewaxed and placed in Bouin’s fixative (HT10-1-32; Sigma-Aldrich) at 56°C for 10 minutes. After washing slides in tap water and distilled H2O, slides were stained with hematoxylin (HT10-79; Sigma-Aldrich) for 5 minutes. After washing in running tap water and distilled H2O, slides were destained once with HCl-alcohol (1:1) and rinsed again in distilled H2O. Next, slides were put in Biebrich scarlet-scid fuchsin (HT151-250ML; Sigma-Aldrich) diluted 1:2 in 1% acetic acid (K45741563 425; Dr. Grogg Chemie, Stettlen, Switzerland) for 1 minute. Slides were rinsed and stained with phosphomolybdic-phosphotungstic acid (HT153-250ML and HT152-250ML; Sigma) 1:1 for 5 minutes. Slides then were stained with Aniline Blue (HT154-250ML; Sigma) for 20 minutes. After a last rinse, slides were put in 0.75% acetic acid, dehydrated, and mounted with Eukitt (Kindler).

**Measurement of ALT, AST, and ALP in Serum**

The liver injury markers ALT and AST were measured on the Cobas 8000 modular analyzer using the module C502 (Roche, Switzerland). ALP likewise was measured on the Cobas 8000, using the module C702 (Roche, Switzerland). All measurements were performed following the manufacturer’s instructions.

**Electron Microscopy**

Sample preparation and electron microscopy were performed as published previously. A variance in the cited protocol was used. In the lanthanide fixation step, samples were incubated in a water bath for 15 minutes at 50°C, without a prior incubation at room temperature. Transmission electron microscopy images were acquired using a Philips CM 12 microscope (Philips/Fei, Hillsboro, OR).

**Flow Cytometry**

Antibodies used for fluorescence-activated cell sorting can be found in Table 1. Livers were perfused with PBS via the portal vein until blanched and then put in Iscove’s modified Dulbecco’s medium (Gibco, Thermo Fisher Scientific, Wall- tham, MA), supplemented with 10% fetal bovine serum. Whole livers were passed through a metal spleen screen and digested with 0.05% collagenase IV (Worthington Biochemi- cal) and DNase I (Sigma-Aldrich) for 30 minutes at 37°C. Intrahepatic mononuclear cells were purified on a Percoll gradient after centrifugation at 1250 x g for 20 minutes without braking. Cells subsequently were washed twice with PBS, and then resuspended in PBS containing 3% fetal bovine serum. Aliquots of 10^6 cells/100 µL of staining buffer per well were incubated each with 1 µg of purified anti-CD16/CD32 for 20 minutes in the dark to block nonspecific binding of antibodies to the Fc receptor of γIII and II receptors (FcγIII- and II). Cell suspensions were incubated with cell viability dye eFluor 506 (Thermo Fisher Scientific) for 20 minutes at 4°C in the dark to exclude dead cells. Subsequently, these cells were stained separately with the following surface markers for 15 minutes with 1 µg of primary antibodies (Table 1). For cytokines and transcription factors, cells first were stained with antibodies to surface antigens, subsequently fixed, and permeabilized according to the manufacturer’s instructions (Foxp3/Transcription Factor Staining Buffer Set; eBioscience). Corresponding fluorochrome-labeled isotype control antibodies were used for staining controls. Cells resuspended in 250 µL of buffer (0.15 mol/L NaCl, 1 mmol/L Na2HPO4, H2O, 10 mmol/L Na2HPO4, 2H2O, and 3 mmol/L NaN3) were analyzed in a flow cytometer (BD LSR II; BD Pharmingen, Inc, San Diego, CA) using the corresponding BD FACS DIVA software. Flow cytometric analysis was performed using FlowJo software (Treestar, Inc, Ashland, OR).

**Western Blot**

Total protein was extracted from liver tissue or cultured cells using RIPA lysis buffer and a TissueLyser II (Qiagen, Hilden, Germany). Lysates were centrifuged for 15 minutes at 20,000 x g, and the supernatant was aliquoted. Protein concentrations were quantified by Bradford assay (5000006; Bio-Rad, Cressier, Switzerland) and a microplate reader. Precast gels (456-1094; Bio-Rad) were used to separate equalized amounts of protein per sample by

---

*Figure 8. (See previous page). Claudin-3 contributes to optimal liver regeneration. (A and B) Immunofluorescent staining of anti-Ki67 (green) or anti-pH3 (red) in liver tissue after PHx, comparing Cldn3+/+ and Cldn3−/− livers. DAPI in blue. Quantification of the proliferation scores below (0 h and 48 h: n = 7 for Cldn3+/+ and n = 6 for Cldn3−/−; 72 h: n = 8, bars represent the means ± SEM, **P < .01, unpaired t test). Representative images were taken. (C) Comparative real-time qPCR determining the cell-cycle–related gene expression after PHx (24 h: n = 5 for Cldn3+/+ and n = 4 for Cldn3−/−; 48 h: n = 7 for Cldn3+/+ and n = 6 for Cldn3−/−; 72 h: n = 8, bars represent mean ± SEM, *P < .05, **P < .01, ***P < .001, unpaired t test). (D) Volcano plot showing up-regulated and down-regulated genes (red circles and blue circles, respectively) in Cldn3+/+ compared with Cldn3−/− liver tissue at 48 hours after PHx. RNA-seq analysis is performed by DESeq2 (n = 3, differential expression significance threshold: P value adjusted < .05). Genes with low expression in Cldn3−/− are shown in blue, and with high expression in red circles. A selection of significantly regulated genes that were identified with Metascape analysis are annotated. Metascape analysis of the (E) top 10 up-regulated and (F) top 10 down-regulated gene pathways within the data set of panel D. Microscopes used for image acquisition in this figure were as follows: panoramic 250 Flash III, 3DHISTECH, panoramic scanner software, with a 20× objective. ECM, extracellular matrix.*
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, under reducing conditions. Proteins were transferred on nitrocellulose membranes (170-3458; Bio-Rad). Membranes were blocked with 5% w/v nonfat dry milk in PBS for 1 hour at room temperature. Primary antibodies were diluted in the blocking medium and incubated overnight at 4°C. Primary antibodies were as follows: claudin-3 (NBP1-35668, 1:500–1:1000; Novus Biologicals); cytokeratin 7 (NBP1-88080, 1:200; Novus Biologicals); and anti–β-actin–horseradish peroxidase (A3854, 1:50,000; Sigma-Aldrich); the secondary antibody used was anti-rabbit–horseradish peroxidase (P0448, 1:2000; Dako).

After primary antibody incubation, membranes were washed 3 times for 5 minutes in PBS-Tween-20 (0.1%). Secondary antibodies were diluted with 5% w/v nonfat dry milk in PBS, and the membranes were incubated for 1 hour at room temperature, followed by 3 washing steps for 30 minutes in total. Enhanced chemiluminescence solution (NEL105001EA; PerkinElmer, Waltham, MA) was added for 1 minute to develop the signal. Films in combination with a developer (AGFA, CURIX 60, Mortsel, Belgium) were used to visualize the bands. The correct band size was estimated with the help of a standard protein ladder (161-0374; Bio-Rad).

Real-Time qPCR mRNA Expression Analysis

RNA from snap-frozen tissue has been extracted using NucleoZOL (740404.200; Macherey-Nagel, Düren, Germany). Complementary DNA was made from 500 ng of tissue RNA using the Omniscript reverse-transcriptase kit (205113; Qiagen). Per reaction, 11.25 ng complementary DNA was used. Real-time qPCRs have been performed on an ABI 7500 thermocycler (Applied Biosystems, Foster City, CA) using TaqMan and on an ABI 7900 HT thermocycler (Applied Biosystems) for the SYBR green–based assays. The corresponding reaction mixtures

### Table 1. Antibodies Used for Fluorescence-Activated Cell Sorting

| Fluorescence | Cell marker | Clone | Company | Catalog no. |
|--------------|-------------|-------|---------|-------------|
| Alexa Fluor 700 | NK1.1 | PK136 | BioLegend (San Diego, CA) | 108730 |
| PE-cy5 | NK1.1 | PK136 | BioLegend | 108716 |
| PE-efluor-610 | Eomes | Dan11mag | eBioscience (San Diego, CA) | 61-4875-82 |
| APC | Rort | AFKJ-9 | eBioscience | 17-6988-80 |
| APC-efluor780 | PD-1 | J43 | eBioscience | 47-9985-82 |
| eFluor450 | PD-1 | J43 | eBioscience | 48-9985-82 |
| PE | IL-22 | Pol5164 | BioLegend | 516404 |
| Percp-efluor710 | IL-22 | 1H8PWSR | eBioscience | 46-7221-80 |
| PE-cy7 | CD49b | DX5 | BioLegend | 108922 |
| PE-cy7 | CD4 | GK1.5 | eBioscience | 25-0041-81 |
| APC | CD4 | RM4-4 | BioLegend | 116014 |
| BV570 | CD8 | 53-6.7 | BioLegend | 301038 |
| Alexa Fluor 700 | CD11b | M1/70 | BioLegend | 101222 |
| BV421 | CD49a | Ha31/8 | BD Biosciences (Allschwil, Switzerland) | 740046 |
| APC-efluor780 | INF-γ | XMG1.2 | eBioscience | 47-7311-82 |
| FITC | INF-γ | XMG1.2 | BioLegend | 505806 |
| PE | INF-γ | XMG1.2 | eBioscience | 12-7311-41 |
| PE | CD19 | SJ25C1 | eBioscience | 12-0198-41 |
| PE-Dazzle 594 | CD19 | 6D5 | BioLegend | 115554 |
| BUV395 | CD45 | 30-F11(Ruo) | BD Biosciences | 564279 |
| Percp cy.5.5 | FoxP3 | FJK-16s | BioLegend | 45-5773-80 |
| PE | FoxP3 | FJK-16s | eBioscience | 12-5773-80 |
| PE-Dazzle 594 | CD152 | UC10-4B9 | BioLegend | 106318 |
| APC | IL-10 | JES5-16E3 | BioLegend | 505010 |
| PE | IL-10 | JES3-9D7 | eBioscience | 12-7108-41 |
| FITC | CD69 | H1.2F3 | BioLegend | 104506 |
| PE | Ly6G | RB6-8C5 | eBioscience | 12-8931-81 |
| PE-cy7 | Ly6G | RB6-8C5 | eBioscience | 25-5931-81 |
| APC | F4/80 | BM8 | eBioscience | 17-4801-82 |
| eFluor450 | CD11c | N418 | eBioscience | 48-0114-82 |
| FITC | TNFα | MP6-XT22 | BioLegend | 506304 |
| eFluor506 | Viability dye | – | eBioscience | 65-0866-18 |
| – | CD16/CD32 | 2.4 G2 | BioLegend | 101302 |
(TaqMan, 4914058001 and SYBR green, 00000004913914001; both Sigma-Aldrich) were used. Cycling conditions were chosen according to the vendor instructions of the DNA polymerase master mixes. TaqMan real-time qPCR primers used were as follows: Ccnb1 (Mm03053893_gH; Thermo Fisher Scientific), Birc5 (Mm00599749_m1; Thermo Fisher Scientific), Foxm1 (Mm00514924_m1; Thermo Fisher Scientific), Cldn3a (p21) (Mm00432448_m1; Thermo Fisher Scientific), Tbp (Mm00446971-m1; Thermo Fisher Scientific), Mdr3 (4448892; Thermo Fisher Scientific), Ost1-β (Mm01175040_m1; Thermo Fisher Scientific), and Asbt (Mm00488258_m1; Thermo Fisher Scientific). SYBR real-time qPCR primers used were as follows: Cldn3 forward: GCACCCACCAAGATCCTCTA, Cldn3 reverse: TCACGTGTCC (designed with NCBI Primer-BLAST, Bethesda, MD). Fold- and log2-fold changes in gene expression were computed and visualized using plotPCA() functions from the DESeq2 R package, with default parameters.

RNA Sequencing

Total RNA was extracted from the liver with NucleoZOL (740404.200; Macherey-Nagel), and quantified by a bioanalyzer (Bio-Rad). Sequencing was performed with paired-end reads of 50 bp. TruSeq Stranded mRNA (Illumina, San Diego, CA). Sequencing was performed on a NovaSeq6000 (Illumina).

RNA-seq alignment. Fastq files were aligned to the mouse reference genome mm10 ENSEMBL (European Molecular Biology Laboratory’s European Bioinformatics Institute, Hinxton, Cambridge, UK) release 102 with hisat2 v. 2.2.1, and transformed into bam files with SAMtools v. 1.10. The read count matrix was produced from the bam files via featureCount shell version 2.0.1.

Dimensionality reduction. For the principal component analysis, the read count matrix was variance-stabilizing-transformed using vst(), then principal components were computed and visualized using plotPCA() functions from the DESeq2 R package, with default parameters.

RNA-seq differential expression. Differentially expressed genes were computed with R package DESeq2. Two technical replicates of control sample 5 were analyzed together by collapsing them using the DESeq2 collapseEpilates function. Genes with a P value less than .05 adjusted by false discovery rate were considered statistically significant for further analysis. For volcano plot visualization, log2-fold changes obtained from DESeq2 analysis were shrunk using the apeglm shrinkage estimator.

Enrichment analysis. Metascape was used to determine the pathways to which genes were associated.

Oral Glucose Tolerance Test, Glucose, and Insulin Measurements

Before the oral glucose tolerance test, mice were fasted overnight (16 hours), followed by baseline blood glucose and insulin levels measurements. A bodyweight-adjusted amount of glucose was given by oral gavage (2 mg/g bodyweight). Glucose and insulin levels subsequently were determined. Blood for glucose was obtained by blood collection from the left and right saphenous vein (<1 μL). Blood/serum for insulin measurements was obtained by exsanguination (under anesthesia) via cardiac puncture. Glucose levels were determined with the use of a commercial glucometer (Accu-check Aviva; Hoffmann-La Roche, Basel, Switzerland). Serum insulin levels were determined with the Ultra-Sensitive Mouse Insulin ELISA Kit (90080; Crystal Chem, Elk Grove Village, IL), according to the manufacturer’s instructions.

Bile Acid Quantification

The method applied was described recently. Briefly, for quantification of bile acids, 25-μL serum samples diluted 1:4 with water, and calibrators, were subjected to protein precipitation by adding 900 μL of 2-propanol and a mixture of deuterated internal standards. Extraction was performed for 30 minutes at 4°C with continuous shaking, followed by centrifuging at 16,000 × g for 10 minutes. Supernatants were transferred to new tubes, evaporated to dryness, and reconstituted with 100 μL methanol:water (1:1, v/v). For the extraction of liver samples, 900 μL of chloroform:methanol:water (1:3:1, v/v/v) and 100 μL internal standard mixture were added to a Precellys tube (VWR, Radnor, PA) containing beads and 30 ± 5 mg of liver tissue. Samples were homogenized with a Precellys tissue homogenizer, and centrifuged at 16,000 × g for 10 minutes at 20°C. The supernatant was transferred to a new tube and the procedure was repeated by adding 800 μL extraction solvent. After evaporation to dryness, samples were resuspended with 200 μL methanol:water (1:1, v/v). The injection volume in both cases was 3 μL. Liquid chromatography–tandem mass spectrometry consisted of an Agilent 1290 ultra performance liquid chromatography coupled to an Agilent 6490 triple quadrupole mass spectrometer equipped with an electrospray ionization source (Agilent Technologies, Basel, Switzerland). Chromatographic separation of bile acids was achieved using a reversed-phase column (Acquity UPLC BEH C18, 1.7 mm, 2.1 μm, 150 mm; Waters, Wexford, Ireland).

Measurement of Serum Proinflammatory Cytokines

Serum cytokines were determined on a cytokine array. The array was performed by Eve technologies (Calgary, Canada), using the following application: Chemokine Array 31-Plex (MD31), based on Millipore Milliplex (Merck, Darmstadt, Germany).

Statistical Tests Used to Analyze Data

The statistical tests used to analyze the data are fitted for each experiment and are described within each figure legend. All authors had access to the study data and have reviewed and approved the final manuscript.
References

1. Zini H, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol 2016;17:564–580.

2. Hwang I, Yang H, Kang H-S, Ahn C-H, Lee G-S, Hong E-J, An B-S, Jung EM, Jeung EB. Tissue-specific expression of occludin, zona occludens-1, and junction adhesion molecule A in the duodenum, ileum, colon, kidney, liver, lung, brain, and skeletal muscle of C57BL mice. J Physiol Pharmacol 2013;64:11–18.

3. Pradhan-Sundd T, Monga SP. Blood-bile barrier: morphology, regulation, and pathophysiology. Gene Expression 2019;19:69–87.

4. Ding L, Lu Z, Lu Q, Chen Y-H. The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manag Res 2013;5:367–375.

5. Günsel D, Yu ASL. Claudins and the modulation of tight junction permeability. Physiol Rev 2013;93:525–569.

6. Colegio OR, Van Itallie CM, McCrea HJ, Rahner C, Anderson JM. Claudins create charge-selective channels in the paracellular pathway between epithelial cells. Am J Physiol Cell Physiol 2002;283:C142–C147.

7. Tabaries S, Siegel PM. The role of claudins in cancer metastasis. Oncogene 2017;36:1176–1190.

8. Lal-Nag M, Morin PJ. The claudins. Genome Biol 2009;10:235.

9. Evans MJ, von Hahn T, Tschere DM, Syder AJ, Panis M, Wölk B, Hatzioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801–805.

10. Benedicto I, Molina-Jimenez F, Bartosch B, Cosset F-L, Lavillette D, Prieto J, Moreno-Otero R, Valenzuela-Fernandez A, Aldabe R, Lopez-Cabrera M, Majano PL. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 2009;83:8012–8020.

11. Meertens L, Bertaux C, Cukierman L, Cormier E, Lavillette D, Cosset F-L, Dragic T. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol 2008;82:3555–3560.

12. Fujita K, Katakura J, Horiguchi Y, Sonoda N, Furuse M, Tsukita S, C-lostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett 2000;476:258–261.

13. Roehlen N, Roca Suarez AA, El Saghire H, Saviano A, Schuster C, Luberger J, Baumert TF. Tight junction proteins and the biology of hepatobiological disease. Int J Mol Sci 2020;21:825.

14. Tanaka H, Yamamoto Y, Kashihara H, Yamazaki Y, Tani K, Fujioyshi Y, Mineta K, Takeuchi K, Tamura A, Tsukita S. Claudin-21 has a paracellular channel role at tight junctions. Mol Cell Biol 2016;36:954–964.

15. Hadj-Rabia S, Baala L, Vabres P, Hamel-Teillac D, Jacquemin E, Fabre M, Lyonnnet S, de Prost Y, Munnich A, Hadchouel M, Smahi A. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology 2004;127:1386–1390.

16. Baala L, Hadij-Rabia S, Hamel-Teillac D, Hadchouel M, Prost C, Leal SM, Jacquemin E, Sefiani A, de Prost Y, Courtois G, Munnich A, Lyonnnet S, Vabres P. Homozygosity mapping of a locus for a novel syndromic ichthyosis to chromosome 3q27–q28. J Invest Dermatol 2002;119:70–76.

17. Matsumoto K, Yamazaki Y, Tanaka H, Watanabe M, Eguchi H, Nagano H, Hikita H, Tatsumi T, Takehara T, Tamura A, Tsukita S. Claudin-2 deficiency reduces bile flow and increases susceptibility to cholesterol gallstone disease in mice. Gastroenterology 2014;147:1134–1145, e10.

18. Bouchagier KA, Assimakopoulos SF, Karavias DD, Maroulis I, Tzelepi V, Kalofonos H, Karavias DD, Kardamakis D, Scopa CD, Tsamandas AC. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients’ survival. In Vivo 2014;28:315–326.

19. Milatz S, Krug SM, Rosenthal R, Günsel D, Müller D, Schulzke J-D, Amasheh S, Fromm M. Claudin-3 acts as a sealing component of the tight junction for ions of either charge and uncharged solutes. Biochim Biophys Acta 2010;1798:2048–2057.

20. Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 2001;120:411–422.

21. Tanaka H, Imasato M, Yamazaki Y, Matsumoto K, Kunimoto K, Delpiere J, Meyer K, Zerial M, Kitamura N, Watanabe M, Tamura A, Tsukita S. Claudin-3 regulates bile canalicular paracellular barrier and cholesterol gallstone core formation in mice. J Hepatol 2018;69:1308–1316.

22. Garcia-Hernandez V, Quiros M, Nusrat A. Intestinal epithelial Claudins: expression and regulation in homeostasis and inflammation: intestinal epithelial Claudins. Ann N Y Acad Sci 2017:1397:66–79.

23. Ahmad R, Rah B, Bastola D, Dhanaw P, Singh AB. Obesity-induces organ and tissue specific tight junction restructurizing and barrier deregulation by claudin switching. Sci Rep 2017;7:5125.

24. Patel RM, Myers LS, Kurundkar AR, Maheshwari A, Nusrat A, Lin PW. Probiotic bacteria induce maturation of intestinal Claudin 3 expression and barrier function. Am J Pathol 2012;180:626–635.

25. Sanchez-Taltavull D, Perkins TJ, Dommann N, Melin N, Keogh A, Candinas D, Strada D, Beldi G. Bayesian correlation is a robust gene similarity measure for single-cell RNA-seq data. NAR Genom Bioinform 2020;2:qkaa002.

26. Castro Dias M, Coisne C, Lazarevic I, Baden P, Hata M, Iwamoto N, Francisco DMF, Vanlandewijck M, Xu L, Baier FA, Stroka D, Beldi G, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Bieniek PK, McKeating JA, Bienia...
28. Fickert P, Wagner M. Biliary bile acids in hepatobiliary injury – what is the link? J Hepatol 2017;67:619–631.

29. Woo S-L, Guo T, Wu C. Hepatic lipogenesis: nutritional control and pathophysiological relevance. In: Ntambi JM, ed. Hepatic de novo lipogenesis and regulation of metabolism. Cham, Basel, Switzerland: Springer International Publishing, 2016:211–234.

30. Ogrodnik M, Miwa S, Tchkhonia T, Tiniakos D, Wilson CL, Lahat A, Day CP, Burt A, Palmer A, Ansee OM, Grellscheid SN, Hoeijmakers JHJ, Barnhoorn S, Mann DA, Bird TG, Vermeij WP, Kirkland JL, Passos JF, von Zglinicki T, Jurk D. Cellular senescence drives age-dependent hepatic steatosis. Nat Commun 2017;8:15691.

31. Luo D, Li J, Chen K, Yin Y, Fang Z, Pang H, Rong X, Guo J. Study on metabolic trajectory of liver aging and the effect of Fufang Zhenzhujiao ti on aging mice. Front Pharmacol 2019;10:926.

32. Hunt NJ, Kang SW, Lockwood GP, Le Couteur DG, Hunt NJ, Kang SW, Lockwood GP, Le Couteur DG. Hallmarks of aging in the liver. Comput Struct Biotechnol J 2019;17:1151–1161.

33. Fiorucci S, Biagioli M, Zampella A, Distrutti E. Bile acids activated receptors regulate innate immunity. Front Immunol 2018;9:1853.

34. Sato Y, Koyama S, Tsukada K, Hatakeyama K. Acute portal hypertension reflecting shear stress as a trigger of liver regeneration following partial hepatectomy. Surg Today 1997;27:518–526.

35. Takakuwa Y, Kokai Y, Sasaki K, Chiba H, Tobioka H, Mori M, Sawada N. Bile canalicul barrier function and expression of tight-junctional molecules in rat hepatocytes during common bile duct ligation. Cell Tissue Res 2002;307:181–189.

36. Kojima T. Tight junction proteins and signal transduction pathways in hepatocytes. Histol Histopathol 2005;68:349.

37. Sakaguchi T, Suzuki S, Higashi H, Inaba K, Nakamura S, Moriyama T, Asano H, Ishikawa M, Hasegawa M. Expression of tight-junctional molecules in rat hepatocellular carcinoma. J Surg Res 2008;147:123–131.

38. D’Agnillo F, Williams MC, Moayeri M, Warfel JM. Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions. PLoS One 2013;8:e62576.

39. Holczbauer Á, Gyöngyősi B, Lotz G, Törzsök P, Kaposi-Novák P, Szijártó A, Tátrai P, Kupcsilik P, Schaff Z, Kiss A. Increased expression of claudin-1 and claudin-7 in liver cirrhosis and hepatocellular carcinoma. Pathol Oncol Res 2014;20:493–502.

40. Inai T, Sengoku A, Guan X, Hirose E, Iida H, Shibata Y. Heterogeneity in expression and subcellular localization of tight junction proteins, claudin-10 and -15, examined by RT-PCR and immunofluorescence microscopy. Arch Histol Cytol 2005;68:349–360.

41. Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A 1999;96:511–516.

42. D’Souza T, Sherman-Baust CA, Poosala S, Mullin JM, Morin PJ. Age-related changes of claudin expression in mouse liver, kidney, and pancreas. J Gerontology A Biol Sci Med Sci 2009;64A:1146–1153.

43. Gebhardt R, Matz-Soja M. Liver zonation: novel aspects of its regulation and its impact on homeostasis. World J Gastroenterol 2014;20:8491–8504.

44. Kietzmann T. Metabolic zonation of the liver: the oxygen gradient revisited. Redox Biol 2017;11:622–630.

45. Halpern KB, Shenhav R, Matcovitch-Natan O, Toth B, Lenze D, Golan M, Massasa EE, Baydatch S, Landen S, Moor AE, Brandis A, Giladi A, Avi hail AS, David E, Amit I, Itzkovitz S. Single-cell spatial reconstruction reveals global division of labour in the mammalian liver. Nature 2017;542:352–356.

46. Macpherson AJ, Heikenwalder M, Ganal-Vonarburg SC. The liver at the nexus of host-microbial interactions. Cell Host Microbe 2016;20:561–571.

47. Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab 2012;16:414–419.

48. Meng Z, Liu N, Fu X, Wang X, Wang Y, Chen W, Zhang L, Forman BM, Huang W. Insufficient bile acid signaling impairs liver repair in CYP27a–/– mice. J Hepatol 2011;55:885–895.

49. Pratt-Hyatt M, Lickteig AJ, Klaassen CD. Tissue distribution, ontogeny, and chemical induction of aldo-keto reductases in mice. Drug Metab Dispos 2013;41:1480–1487.

50. Herrema H, Meissner M, van Dijk TH, Brufau G, Boverhof R, Oosterveer MH, Reijngoud D-J, Müller M, Stellaard F, Groen AK, Kuipers F. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor-controlled metabolic pathways in mice. Hepatology 2010;51:806–816.

51. Nikolaou N, Gathercole LL, Marchand L, Althari S, Dempster NJ, Green CJ, van de Bunt M, McNeil C, Arvaniti A, Hughes BA, Gills RS, Marschall H-U, Penning TM, Ryan J, Arlt W, Hudson L, Tomlinson JW. AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. Metabolism 2019;99:67–80.

52. Thekkinghat AA, Yadav KK, Rangarajan PN. Apolipoprotein L9 interacts with LC3/GABARAP and is a microtubule-associated protein with a widespread subcellular distribution. Biol Open 2019;8:bio045930.

53. Snyder JM, Zhong G, Hogarth C, Huang W, Topping J, LaFrance J, Palau L, Czuba LC, Griswold M, Ghiaur G, Marschall H-U, Penning TM, Ryan J, Arlt W, Hudson L, Tomlinson JW. AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. Metabolism 2019;99:67–80.

54. Pavličová N, Golocorbin-Kon S, Danič M, Stanimirov B, Al-Salami H, Stankov K, Mikov M. Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. Front Pharmacol 2018;9:1283.

55. Zou Y, Bao Q, Kumar S, Hu M, Wang G-Y, Dai G. Four waves of hepatocyte proliferation linked with three waves of hepatic fat accumulation during partial hepatocyte-induced liver regeneration. PLoS One 2012;7:e30675.

56. Brasaemle DL. Cell biology: enhanced: a metabolic push to proliferate. Science 2006;313:1581–1582.
82. Penno CA, Arsenijevic D, Da Cunha T, Kullak-Uidblick GA, Montani J-P, Odermatt A. Quantification of multiple bile acids in uninephrectomized rats using ultra-performance liquid chromatography-tandem mass spectrometry. Anal Methods 2013;5:1155.

Received August 18, 2020. Accepted April 6, 2021.

Correspondence
Address correspondence to: Deborah Stroka, PhD, Department for BioMedical Research, University of Bern, Murtenstrasse 35, 3008 Bern, Switzerland. e-mail: deborah.stroka@dbmr.unibe.ch; fax: (41)31 382 45 08.

Acknowledgements
The authors thank the Next Generation Sequencing platform at the University of Bern for their technical assistance with the RNAseq experiments. The authors also would like to acknowledge Carlos Wotzkow and Dr Fabian Blank from the Live Cell Imaging facility in Bern for their assistance with microscopy. Light and electron microscopy were performed on devices supported by the Microscopy Imaging Center of the University of Bern. The authors thank Donna Emge for creation of the Oil-Red-O staining protocol. The authors thank Nicolas Melin for his critical reading of the manuscript.

CRediT Authorship Contributions
Felix Alexander Baier, PhD (Conceptualization: Supporting; Data curation: Lead; Formal analysis: Lead; Visualization: Lead; Writing – original draft: Equal; Writing – review & editing: Equal)
Daniel Sánchez-Taltavull, PhD (Formal analysis: Supporting; Methodology: Supporting; Software: Supporting; Visualization: Supporting; Writing – review & editing: Supporting)

Tural Yarahmadov, PhD (Formal analysis: Supporting; Methodology: Supporting; Software: Supporting; Validation: Supporting; Visualization: Supporting; Writing – review & editing: Supporting)
Cristina Gómez Castellà, PhD (Formal analysis: Supporting; Methodology: Supporting; Resources: Supporting; Software: Supporting; Validation: Supporting)

Fadi Jebbawi, PhD (Formal analysis: Supporting; Methodology: Supporting; Resources: Supporting; Software: Supporting; Validation: Supporting)

Adrian Keogh, PhD (Methodology: Supporting; Resources: Supporting; Validation: Supporting; Writing – review & editing: Supporting)

Riccardo Tombolini, - (Methodology: Supporting; Resources: Supporting)

Adolfo Odriozola, - (Methodology: Supporting; Resources: Supporting)
Mariana Castro Dias, PhD (Resources: Supporting)

Urban Deutsch, PhD (Resources: Supporting; Writing – review & editing: Supporting)

Mikio Furuse, Prof (Resources: Supporting)

Britta Engelhardt, Prof (Funding acquisition: Supporting; Resources: Supporting; Writing – review & editing: Supporting)

Benoit Zuber, Prof (Funding acquisition: Supporting; Resources: Supporting; Writing – review & editing: Supporting)

Alex Odermatt, Prof (Funding acquisition: Supporting; Resources: Supporting; Writing – review & editing: Supporting)

Daniel Candinas, Prof (Funding acquisition: Supporting)

Deborah Stroka, Prof (Conceptualization: Lead; Formal analysis: Lead; Funding acquisition: Lead; Investigation: Equal; Project administration: Lead; Resources: Supporting; Supervision: Lead; Validation: Lead; Writing – original draft: Equal; Writing – review & editing: Equal)


Conflicts of interest
The authors disclose no conflicts.

Funding
Supported by Swiss National Science Foundation grant numbers 173157 (D.S.), 189080 (B.E.), 179520 (B.Z.), and 179400 (A.I.O.). The European Union Seventh Framework Program FP7 under grant agreements 241861 (Blood-brain barrier JUnctionS as Targets for paracellular drug delivery to the BRAIN) and 607962 (Neuroinflammation).